Annual report pursuant to Section 13 and 15(d)

Discontinuing Operations - Additional Information (Details)

v3.21.1
Discontinuing Operations - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Oct. 24, 2019
Jul. 15, 2019
Jul. 05, 2019
Dec. 31, 2020
Sep. 30, 2019
Dec. 31, 2020
Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Excess consideration note matured amount $ 6,000            
Net receivable, current             $ 747
Earn-Out from siParadigm, less current portion       $ 0   $ 0 356
Advance from siParadigm, less current portion       0   0 252
Earn-Out from siParadigm, current portion       91   $ 91 747
Clinical Agreement              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Cash consideration received, total     $ 747        
Cash consideration received for equipment     45        
Advance from NovellusDx, Ltd.     1,000        
Supplier invoices paid directly to related party     298        
Cash consideration, adjustment     11        
Transaction costs     $ 110        
Term of contract     24 months        
Period of service     12 months        
Percent withheld from monthly payment         25.00% 75.00%  
Non-compete term     3 years        
Excess Consideration Note              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Excess consideration note             888
siParadigm              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Advance, current       0   $ 0 566
Advance from siParadigm, less current portion             252
Partners for Growth, Biosciences and Interpace BioPharma              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Advance, current       15   15  
BioPharma Disposal              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Gross sales price   $ 23,500          
Closing adjustments   2,000          
Promissory note receivable   7,700          
Cash received from transaction   2,300          
Interest rate 6.00%            
Interest expense $ 24            
Net worth adjustment 775            
Net sales price 153            
Security for indemnification obligations $ 735            
BioPharma Disposal | TSA              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Related party shared expenses           217 186
BioPharma Disposal | TSA, reimbursement portion              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Related party shared expenses       $ 155     188
Secured Debt | PFG              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Term note, principal balance   6,000          
Discontinuing Operations              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Interest expense           $ 0 2,211
Discontinuing Operations | BioPharma Disposal              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Gross sales price   23,500          
Net sales price   $ 19,099          
Discontinuing Operations | Convertible Debt              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Interest expense, debt             $ 1,500